| Drug General Information |
| Drug ID |
D0939G
|
| Drug Name |
Quisinostat
|
| Indication |
Advanced stage follicular lymphoma [ICD9: 202; ICD10:C82]
|
Phase 2 |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Histone deacetylase 4 |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
Alcoholism
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesis
|
|
MicroRNAs in cancer
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
Pathway Interaction Database
|
Signaling events mediated by HDAC Class II
|
|
Signaling events mediated by HDAC Class III
|
|
Signaling events mediated by HDAC Class I
|
|
Sumoylation by RanBP2 regulates transcriptional repression
|
|
Validated nuclear estrogen receptor alpha network
|
|
Reactome
|
NOTCH1 Intracellular Domain Regulates Transcription
|
|
Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
|
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
|
|
WikiPathways
|
Endochondral Ossification
|
|
Cardiac Hypertrophic Response
|
|
Neural Crest Differentiation
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
TarBasePathway
|
|
Cell Cycle
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01486277) A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma |
|---|
| REF 2 | Wikipedia: Quisinostat |
|---|
